Full Text View
Tabular View
No Study Results Posted
Related Studies
Disease-modifying Potential of Transdermal NICotine in Early Parkinson's Disease (NIC-PD)
This study is currently recruiting participants.
Verified May 2013 by University of Vermont
Study NCT01560754   Information provided by University of Vermont

First Received on March 9, 2012.   Last Updated on May 8, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Parkinson's Disease
Additional conditions recognized in this trial
Parkinson Disease
More general conditions related to this trial
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Interventions listed in this trial
nicotine transdermal patch
Additional drug interventions recognized in this trial
Nicotine
Nicotine polacrilex
More general drug interventions related to this trial
Autonomic Agents
Central Nervous System Agents
Central Nervous System Stimulants
Cholinergic Agents
Cholinergic Agonists
Ganglionic Stimulants
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Nicotinic Agonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
James BOYD MD
Michael J. Fox Foundation for Parkinson's Research


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services